243 related articles for article (PubMed ID: 28234780)
1. Biologics for asthma and allergy.
Walsh GM
Curr Opin Otolaryngol Head Neck Surg; 2017 Jun; 25(3):231-234. PubMed ID: 28234780
[TBL] [Abstract][Full Text] [Related]
2. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.
Walsh GM
Expert Rev Clin Immunol; 2017 Feb; 13(2):143-149. PubMed ID: 27459348
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
4. An update on biologic-based therapy in asthma.
Walsh GM
Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-4/-13 based therapy in asthma.
Walsh GM
Expert Opin Emerg Drugs; 2015 Sep; 20(3):349-52. PubMed ID: 26021492
[TBL] [Abstract][Full Text] [Related]
6. The use of biologic therapies for the management of pediatric asthma.
Lovinsky-Desir S
Pediatr Pulmonol; 2020 Mar; 55(3):803-808. PubMed ID: 31880870
[TBL] [Abstract][Full Text] [Related]
7. An update on emerging drugs for asthma.
Walsh GM
Expert Opin Emerg Drugs; 2012 Mar; 17(1):37-42. PubMed ID: 22292562
[TBL] [Abstract][Full Text] [Related]
8. Reslizumab in the treatment of severe eosinophilic asthma: an update.
Walsh GM
Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
[TBL] [Abstract][Full Text] [Related]
9. Biologics and Allergy Immunotherapy in the Treatment of Allergic Diseases.
Cox L
Immunol Allergy Clin North Am; 2020 Nov; 40(4):687-700. PubMed ID: 33012328
[TBL] [Abstract][Full Text] [Related]
10. Biologic targeted therapy in allergic asthma.
Bice JB; Leechawengwongs E; Montanaro A
Ann Allergy Asthma Immunol; 2014 Feb; 112(2):108-15. PubMed ID: 24468249
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment.
Walsh GM
Adv Pharmacol; 2023; 98():31-54. PubMed ID: 37524491
[TBL] [Abstract][Full Text] [Related]
12. Selecting the right biologic for your patients with severe asthma.
Manka LA; Wechsler ME
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):406-413. PubMed ID: 30056149
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of targeting interleukin 5 in asthma.
Walsh GM
BioDrugs; 2013 Dec; 27(6):559-63. PubMed ID: 23728885
[TBL] [Abstract][Full Text] [Related]
14. Biologics in the treatment of severe asthma.
Quirce S; Phillips-Angles E; Domínguez-Ortega J; Barranco P
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():45-49. PubMed ID: 29108767
[TBL] [Abstract][Full Text] [Related]
15. [Inflammatory cytokines (IL-4, IL-5 and IL-13)].
Maeda S; Yanagihara Y
Nihon Rinsho; 2001 Oct; 59(10):1894-9. PubMed ID: 11676128
[TBL] [Abstract][Full Text] [Related]
16. Biologics in asthma: difficulties and drawbacks.
Bousquet J; Chiron R; Humbert M
Expert Opin Biol Ther; 2008 Dec; 8(12):1921-8. PubMed ID: 18990078
[TBL] [Abstract][Full Text] [Related]
17. Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes.
Kau AL; Korenblat PE
Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):570-5. PubMed ID: 25159182
[TBL] [Abstract][Full Text] [Related]
18. Novel monoclonal treatments in severe asthma.
Meteran H; Meteran H; Porsbjerg C; Backer V
J Asthma; 2017 Dec; 54(10):991-1011. PubMed ID: 28287273
[TBL] [Abstract][Full Text] [Related]
19. Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?
Parulekar AD; Diamant Z; Hanania NA
Curr Opin Pulm Med; 2017 Jan; 23(1):3-11. PubMed ID: 27820746
[TBL] [Abstract][Full Text] [Related]
20. Targeting key proximal drivers of type 2 inflammation in disease.
Gandhi NA; Bennett BL; Graham NM; Pirozzi G; Stahl N; Yancopoulos GD
Nat Rev Drug Discov; 2016 Jan; 15(1):35-50. PubMed ID: 26471366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
